Belite Bio BLTE
NASDAQ BLTE
$186.29 +15.20 (+8.88%)
As of: Sep 4, 2026 · 2:37 PM EDT

Belite Bio (BLTE) Income towards Parent Company (2022 - 2026)

Belite Bio (BLTE) posted quarterly Income towards Parent Company of -$26.9 million for Q1 2026, down 88.68% year-over-year from -$238.0 million in Q1 2025, and up 99.89% quarter-over-quarter from -$25.3 billion in Q4 2025.

Analysis

Belite Bio (BLTE) Income towards Parent Company (2022 - 2026) Analysis & Trends

Belite Bio's Income towards Parent Company history runs 5 years deep, the most recent figure standing at -$26.9 million for Q1 2026.

  • In Q1 2026, Income towards Parent Company fell 88.68% year-over-year to -$26.9 million; the TTM figure through Mar 2026 stood at -$63.4 billion (down 124.04% YoY), while the FY2025 annual figure was -$77.5 million, down 131.85% from the prior year.
  • Income towards Parent Company for Q1 2026 stood at -$26.9 million, up from -$25.3 billion in the prior quarter.
  • The five-year high for Income towards Parent Company was -$6.8 million in Q4 2022, with the low at -$25.3 billion in Q4 2025.
  • The 5-year median for Income towards Parent Company is -$6.9 billion (2023), against an average of -$7.4 billion.
  • The sharpest annual moves came in 2024 and 2025: Income towards Parent Company tumbled 144392.13% in 2024, then soared 99.82% in 2025.
  • Belite Bio's Income towards Parent Company stood at -$6.8 million in 2022, then dropped by 3.05% to -$7.0 million in 2023, then sank by 144392.13% to -$10.1 billion in 2024, then plunged by 150.73% to -$25.3 billion in 2025, then soared by 99.89% to -$26.9 million in 2026.
  • Business Quant data shows BLTE's Income towards Parent Company at -$26.9 million in Q1 2026, -$25.3 billion in Q4 2025, and -$21.7 billion in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.77 Bn 130.92 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.51 Bn 77.52 Bn 3.93 Bn
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn
4 Moderna 58.20 Bn 53.06 Bn 52.00 Mn
5 Revolution Medicines 44.04 Bn 44.04 Bn -
6 BeOne Medicines 39.99 Bn 34.89 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.45 Bn 32.14 Bn 992.69 Mn
8 Royalty Pharma 28.40 Bn 27.56 Bn -
9 Insmed 27.44 Bn 26.28 Bn 358.27 Mn
10 Belite Bio 6.25 Bn 6.25 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -28.41 Mn
Mar 31, 2026 -26.94 Mn
Dec 31, 2025 -253.24
Sep 30, 2025 -21.69 Mn
Jun 30, 2025 -16.32 Mn
Mar 31, 2025 -14.28 Mn
Dec 31, 2024 -101.00
Sep 30, 2024 -8.68 Mn
Jun 30, 2024 -9.49 Mn
Mar 31, 2024 -7.87 Mn
Dec 31, 2023 -6.99 Mn
Sep 30, 2023 -10.94 Mn
Jun 30, 2023 -68.12
Mar 31, 2023 -6.90 Mn
Dec 31, 2022 -6.78 Mn
Jun 30, 2022 -2.39 Mn